Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 300 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Tuochuan D.

United States

USD 300 /hr

Treg Therapy Expert | Translating Complex Data into Business Growth & Investment Narratives

Profile Summary

As a PhD Biostatistician and strategic leader in biotech, I bridge the gap between deep scientific insight and commercial growth. My expertise spans the full clinical development lifecycle for novel therapies—from small molecules to pioneering Treg cell therapies—and extends into Business Development and Fundraising strategy. At Avotres Inc., a pioneer in next-generation Treg therapies, I gained rare, end-to-end insight into this transformative modality, from its foundational biology and CMC to clinical development. This hands-on experience allows me to not only de-risk scientific pathways but also to craft compelling investment narratives and partnership strategies that align technical milestones with market value and investor expectations. I partner with biotech founders and executives to: 1. Translate complex data into clear development roadmaps and robust regulatory strategies. 2. Develop and execute BD strategies, including target identification, partnership structuring, and alliance management. 3. Strengthen fundraising materials (pitch decks, data packages, due diligence), articulate a credible path to value inflection, and communicate effectively with potential investors and partners. I am available for consulting projects that require an advisor who understands both the science of Treg/advanced therapies and the business of building a successful biotech company.

Subject Matter Expertise

• ☆ Biostatistics
• ☆ R
• ☆ Drug Development

Services

• Research
• Consulting
• Data & AI

Research Fact Checking, Scientific and Technical Research

Consulting Business Strategy Consulting, Go-to-Market Strategy Consulting, Digital Strategy Consulting, Operations Consulting, Scientific and Technical Consulting, Financial Consulting, Regulatory Consulting, Manufacturing Consulting

Data & AI Statistical Analysis, Data Visualization, Big Data Analytics, Data Insights

Work Experience

Director, Business & Operations

Avotres Inc.

April 2021 - Present

Pricipal Biostatistician

Novartis

March 2014 - March 2021

Statistical programmer

Sanofi

July 2008 - May 2009

Education

Ph.D. Biostatistics

State University of New York at Buffalo

September 2009 - March 2014

Bachelor's Degree in Mathematics and Statistics

Peking University

September 2004 - June 2008

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Dong, Tuochuan, Gaglia, Jason L, Daley, Heather L, Bryant, Nora K, Ritz, Jerome, Skyler, Jay S, Jiang, Hong (2024). Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes .

Dong, Tuochuan, Garrido, Pilar, Pujol, Jean-Louis, Kim, Edward S, Lee, Jay M, Tsuboi, Masahiro, Gómez-Rueda, Ana, Benito, Amparo, Moreno, Nicolas, Gorospe, Luis, et al. (2021). Canakinumab with and Without Pembrolizumab in Patients with Resectable Non-Small-Cell Lung Cancer: CANOPY-N Study Design .

Dong, Tuochuan, Kiladjian, Jean-Jacques, Zachee, Pierre, Hino, Masayuki, Pane, Fabrizio, Masszi, Tamas, Harrison, Claire N, Mesa, Ruben, Miller, Carole B, Passamonti, Francesco, et al. (2020). Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study .

Dong, Tuochuan, Gupta, Vikas, Wolleschak, Denise, Hasselbalch, Hans, Vannucchi, Alessandro Maria, Koschmieder, Steffen, Cervantes, Francisco, Li, Yang, Wroclawska, Monika, Bharathy, Savita, et al. (2020). Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis:A phase 1b/2 dose-finding study .

Tuochuan Dong, Simon T. Durrant, Arnon Nagler, Paola Guglielmelli, David Lavie, Philipp le Coutre, Heinz Gisslinger, Charles Chuah, Margherita Maffioli, Savita Bharathy, et al. (2019). Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis .

Tuochuan Dong, Srdan Verstovsek, Jason Gotlib, Ruben A. Mesa, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francisco Cervantes, Claire N. Harrison, Ronald Paquette, William Sun, et al. (2017). Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses .

Dong, Tuochuan, Wu, Yi-Long, Zhang, L I, Trandafir, Lucia, Duval, Vincent, Hazell, Katharine, Xu, Binghe (2016). Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors .

Dong, Tuochuan, Attwood, Kristopher, Hutson, Alan, Liu, Song, Tian, Lili (2015). A new diagnostic accuracy measure and cut-point selection criterion .

Dong, Tuochuan, Tian, Lili (2014). Confidence Interval Estimation for Sensitivity to the Early Diseased Stage Based on Empirical Likelihood .

Dong, Tuochuan, Kang, Le, Hutson, Alan, Xiong, Chengjie, Tian, Lili (2014). Confidence interval estimation of the difference between two sensitivities to the early disease stage .

Dong, Tuochuan, Tian, Lili, Hutson, Alan, Xiong, Chengjie (2011). Parametric and non‐parametric confidence intervals of the probability of identifying early disease stage given sensitivity to full disease and specificity with three ordinal diagnostic groups .